These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 8626361)

  • 1. The safety profile of nefazodone.
    Robinson DS; Roberts DL; Smith JM; Stringfellow JC; Kaplita SB; Seminara JA; Marcus RN
    J Clin Psychiatry; 1996; 57 Suppl 2():31-8. PubMed ID: 8626361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolerability and safety: essentials in antidepressant pharmacotherapy.
    Lader MH
    J Clin Psychiatry; 1996; 57 Suppl 2():39-44. PubMed ID: 8626362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New antidepressants and the cytochrome P450 system: focus on venlafaxine, nefazodone, and mirtazapine.
    Owen JR; Nemeroff CB
    Depress Anxiety; 1998; 7 Suppl 1():24-32. PubMed ID: 9597349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression.
    Cohn CK; Robinson DS; Roberts DL; Schwiderski UE; O'Brien K; Ieni JR
    J Clin Psychiatry; 1996; 57 Suppl 2():15-8. PubMed ID: 8626358
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nefazodone: aspects of efficacy.
    Rickels K; Robinson DS; Schweizer E; Marcus RN; Roberts DL
    J Clin Psychiatry; 1995; 56 Suppl 6():43-6. PubMed ID: 7649973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
    Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic dose range of nefazodone in the treatment of major depression.
    Robinson DS; Marcus RN; Archibald DG; Hardy SA
    J Clin Psychiatry; 1996; 57 Suppl 2():6-9. PubMed ID: 8626365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy in long-term treatment of depression.
    Montgomery SA
    J Clin Psychiatry; 1996; 57 Suppl 2():24-30. PubMed ID: 8626360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Care of the sexually active depressed patient.
    Hirschfeld RM
    J Clin Psychiatry; 1999; 60 Suppl 17():32-5; discussion 46-8. PubMed ID: 10446740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction.
    Montejo AL; Llorca G; Izquierdo JA; Rico-Villademoros F
    J Clin Psychiatry; 2001; 62 Suppl 3():10-21. PubMed ID: 11229449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
    Zajecka JM
    J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nefazodone in the treatment of severe, melancholic, and recurrent depression.
    Marcus RN; Mendels J
    J Clin Psychiatry; 1996; 57 Suppl 2():19-23. PubMed ID: 8626359
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of nefazodone, imipramine, and placebo in patients with moderate to severe depression.
    Feighner JP; Pambakian R; Fowler RC; Boyer WF; D'Amico MF
    Psychopharmacol Bull; 1989; 25(2):219-21. PubMed ID: 2690165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
    Sajatovic M; DiGiovanni S; Fuller M; Belton J; DeVega E; Marqua S; Liebling D
    Clin Ther; 1999 Apr; 21(4):733-40. PubMed ID: 10363738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nefazodone on body weight: a pooled analysis of selective serotonin reuptake inhibitor- and imipramine-controlled trials.
    Sussman N; Ginsberg DL; Bikoff J
    J Clin Psychiatry; 2001 Apr; 62(4):256-60. PubMed ID: 11379839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-year perspectives on the safety and tolerability of nefazodone.
    Dunner DL; Laird LK; Zajecka J; Bailey L; Sussman N; Seabolt JL
    J Clin Psychiatry; 2002; 63 Suppl 1():32-41. PubMed ID: 11890563
    [No Abstract]   [Full Text] [Related]  

  • 17. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
    Wernicke JF; Sayler ME; Koke SC; Pearson DK; Tollefson GD
    Depress Anxiety; 1997; 6(1):31-9. PubMed ID: 9394873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of depression in the elderly.
    Williams GO
    Prim Care; 1989 Jun; 16(2):451-74. PubMed ID: 2664841
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.